DVL1 and prostate carcinoma: Moreover, CK2 has been found to be overexpressed in several human tumors such as malignant peripheral nerve sheath tumors, acute myeloid leukemia, and human prostate cancer.49 In particular, recent data has shown that CK2 and β-catenin can be co-precipitated with Wnt signaling intermediate Dvl, suggesting a crucial role of CK2 in Wnt-driven cancer progression.50 Thus, CK2 seems to be a promising therapeutic target in cancers.